<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714672</url>
  </required_header>
  <id_info>
    <org_study_id>KF8001-01</org_study_id>
    <secondary_id>U1111-1179-2333</secondary_id>
    <secondary_id>KF8001-01</secondary_id>
    <nct_id>NCT03714672</nct_id>
  </id_info>
  <brief_title>Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction</brief_title>
  <official_title>A Randomized, Double-blind, Multi-site, Comparator-controlled, Phase III Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Tramadol Hydrochloride and Diclofenac Sodium in Acute Moderate to Severe Pain After Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grünenthal, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated a new drug fixed-dose combination tablet (FDC) called
      tramadol/diclofenac at two different strengths (fixed doses of 25 milligrams [mg] of tramadol
      and of diclofenac or of 50 mg each). Tramadol and diclofenac each relieve pain, but they do
      so by different mechanisms. They were used alone as comparator drug in this study. Both are
      marketed drugs and are standard treatment for acute pain, including wisdom tooth removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to demonstrate that the FDC of Tramadol and Diclofenac 50/50
      has superior analgesic effect than the monotherapies and that the FDC of Tramadol and
      Diclofenac 25/25 has non-inferior analgesic effect than the monotherapies. There was an
      Enrollment Period, a blinded Treatment Period, and a Follow-up Period. Previously used
      analgesic medication was washed out for at least 24 hours before surgery. The Treatment
      Period starts on Day 1 with dental surgery and treatment allocation. Treatment was started
      within 4 hours after the end of surgery if the participant's pain intensity had reached at
      least 5 points on the 11-point numerical rating scale (NRS). Each participant received 3
      doses of one of the four treatments within 24 hours. One fourth of the participants received
      the fixed-dose combination tablet at a low dose, one fourth at the higher dose, one fourth
      received 50 mg of the comparator tramadol alone, and one fourth 50 mg of the comparator
      diclofenac alone.

      The first 2 doses of the investigational medicinal product (IMP) were taken at the site, the
      last dose in an out-patient setting. Participants returned to the site at 24 hours after the
      first dose. A Follow-up Period included a final visit at the site or a phone call on Day 14
      to assess the participant's safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2017</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study used double-blind and double-dummy methods to guarantee the blinding of all personnel involved in the study. Participants, investigators, and all persons involved in the conduct, data management, and analysis of the study were fully blinded to the participant's treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)</measure>
    <time_frame>Up to 4 hours after first dose</time_frame>
    <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point verbal rating scale (VRS) with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR4) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 4 hours after IMP intake. Minimum and maximum values for TOTPAR4 were 0=worst score and 16=best score, a higher score indicates more pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief at 6 Hours Post-dose (TOTPAR6)</measure>
    <time_frame>Up to 6 hours after first dose</time_frame>
    <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR6) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 6 hours after IMP intake. Minimum and maximum values for TOTPAR6 were 0=worst score and 24=best score, a higher score indicates more pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief at 8 Hours Post-dose (TOTPAR8)</measure>
    <time_frame>Up to 8 hours after first dose</time_frame>
    <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR8) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 8 hours after IMP intake. Minimum and maximum values for TOTPAR8 were 0=worst score and 32=best score, a higher score indicates more pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summed Pain Intensity Difference (SPID) at 4, 6, 8, and 24 Hours Post-dose</measure>
    <time_frame>Baseline; up to 24 hours after first dose</time_frame>
    <description>Pain intensity was assessed by the participant before and at defined time points after the first IMP dose using an 11-point NRS with anchors at 0 for &quot;no pain&quot; and 10 for &quot;pain as bad as you can imagine&quot;. Pain Intensity Difference (PIDt) was defined as the difference between baseline pain intensity and pain intensity at time point t, and SPID defined as summed PIDt x [time (hours) elapsed since previous observation]. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum=10 at each time point], and negative numbers indicate an increase in pain [minimum=-10 at each time point]. The overall minimum and maximum are -10 and 10 times the number of hours specified (SPID-4=[-40 to 40], SPID-6=[-60 to 60], SPID-8=[-80 to 80], and SPID-24=[-240 to 240]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve a 50 Percent Reduction in Baseline Pain (Pain at Least Half Gone)</measure>
    <time_frame>Up to 24 hours after first dose</time_frame>
    <description>Time (hours) when the participant achieved a 50 percent reduction of baseline (starting) pain. It was assessed at defined time points after the first IMP dose using a YES or NO question for pain half gone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of First Perceptible Pain Relief</measure>
    <time_frame>Up to 8 hours after first dose</time_frame>
    <description>Participants used one stopwatch to document the time between first IMP dose and when they begin to feel any pain-relieving effect from the IMP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Meaningful Pain Relief</measure>
    <time_frame>Up to 8 hours after first dose</time_frame>
    <description>Participants used a second stopwatch to document the time between first IMP dose and when they felt their pain relief was meaningful to them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Intake of First Rescue Medication Dose</measure>
    <time_frame>First dose to 24 hours after first dose</time_frame>
    <description>The time from first IMP dose to first dose of rescue medication (ibuprofen or ketorolac), if needed, within 24 hours post-dose was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Evaluation of the Treatment</measure>
    <time_frame>8 hours after the first dose of IMP or before first intake of rescue medication (whatever the first) and 24 hours after the first dose of IMPs</time_frame>
    <description>Participants documented their overall impression of the analgesic efficacy of the IMPs on a 5-point Likert scale from Excellent (4) to Poor (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Type of Adverse Events</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>The incidence of treatment emergent adverse events (TEAE) reported from first dose (Day 1) to last scheduled contact with the participant on Day 14 was descriptively summarized. Selected TEAEs were events with preferred terms of nausea, vomiting, abdominal pain, gastrointestinal bleeding, dizziness, or hypotension.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1151</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol/Diclofenac 50/50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol/Diclofenac 25/25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac 50</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol/Diclofenac 50/50</intervention_name>
    <description>Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
    <arm_group_label>Tramadol/Diclofenac 50/50</arm_group_label>
    <other_name>Adorlan Forte (Registered Trademark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol/Diclofenac 25/25</intervention_name>
    <description>Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
    <arm_group_label>Tramadol/Diclofenac 25/25</arm_group_label>
    <other_name>Adorlan (Registered Trademark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol 50</intervention_name>
    <description>Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
    <arm_group_label>Tramadol 50</arm_group_label>
    <other_name>Tramadol immediate-release capsule</other_name>
    <other_name>Tradol (Registered Trademark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac 50</intervention_name>
    <description>Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
    <arm_group_label>Diclofenac 50</arm_group_label>
    <other_name>Voltaren (Registered Trademark) (diclofenac enteric-coated tablet)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant has read the informed consent form, has understood the relevant
             aspects of the clinical study, and grants his/her authorization to participate by
             signing the informed consent form prior to the inclusion in the clinical study and the
             performance of any procedure.

          2. Male and female participants above 18 years up to 60 years.

          3. Female participants of childbearing potential must be practicing an acceptable method
             of birth control and must have a negative urine pregnancy test at enrollment with
             confirmation at the Allocation Visit.

          4. Participants are in good health, i.e., the medical record, vital signs, physical
             examination, and laboratory parameter assessments do not show any abnormal deviations
             impeding the participation in the clinical study.

          5. Participants requiring extraction of 3 or more third molars with 2 mandibular impacted
             third molars.

          6. Clinical and radiological diagnosis of impacted lower third molars.

          7. Class I and Class II molars according to Pell and Gregory's classification (Gay Escoda
             et al. 2004).

          8. Participants must be able to swallow the IMPs.

        Exclusion Criteria at Enrollment:

          1. Findings in the medical record, vital signs, and/or physical examination demonstrating
             abnormal conditions of participant's general state of health preventing his/her
             participation in the clinical study according to the investigator's opinion.

          2. Participant unable to speak, read, or write in Spanish language.

          3. Clinical laboratory parameters exceed the pre-defined alert ranges (i.e., 1 standard
             deviation above or below the upper/lower limit of the normal ranges).

          4. Known hypersensitivity to the IMPs, the anesthetic to be used during surgery, or to
             the rescue medication (ibuprofen, ketorolac).

          5. Known alcohol or drug abuse in the last 6 months or any history of seizures. Alcohol
             abuse is defined as the consumption of more than 3 ounces (about 90 milliliters) of
             liquor or spirits or 18 ounces (about 530 milliliters) of beer per day, for 5
             consecutive days during the 6-month period. Drug abuse is defined as the use of any
             recreational drug for 5 consecutive days during the 6 month period.

          6. Participants who take analgesic medication for chronic pain, monoamine oxidase
             inhibitors, tricyclic antidepressants, neuroleptics, or other drugs that reduce the
             seizure threshold within 4 weeks of enrollment.

          7. Pregnant or lactating women.

          8. Participants who received systemic corticosteroids or opioid analgesics less than 2
             weeks before surgery.

          9. Participants with molars linked to the mandibular canal.

         10. Participants requiring immediate dental procedures other than third and fourth molars
             extraction,

             Exclusion Criteria at the Allocation Visit:

         11. Participant received a long-acting non-steroidal anti-inflammatory drug within 24
             hours or 5 times the elimination half-life of that drug prior to surgery, whatever the
             longer.

         12. Participant received any analgesic medication other than short-acting pre-operative or
             intra-operative anesthetic agents within 24 hours before taking IMPs.

         13. Participant received more than 300 mg of lidocaine in total.

         14. Participant received any analgesic medication other than the IMPs immediately after
             the oral surgical procedure was completed.

         15. Baseline pain intensity of the participant after oral surgical procedure remains below
             5 points on the 11-point NRS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grünenthal Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Grünenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>CP 45030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>CP 64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>CP 64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Aguascalientes</city>
        <zip>CP 20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Chihuahua</city>
        <zip>CP 31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Leon Guanajuato</city>
        <zip>CP 37160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic</name>
      <address>
        <city>Puebla</city>
        <zip>CP 72160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>CP 78290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Gay Escoda C, Piñera Penalva M, Velasco Vivancos V, Berini Aytés L. Cordales incluidos. Patología, clínica y tratamiento del tercer molar incluído. In: Gay Escoda C, Berini Aytés L. (eds.). Tratado de Cirugía Bucal. Tomo I. Madrid: Ergón; 2004. p. 355-85</citation>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <results_first_submitted>April 15, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wisdom tooth removal</keyword>
  <keyword>Dental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information available on the Grünenthal Group Web Site (see URL below for details).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_url>http://www.grunenthal.com/r-d-vision-mission/clinical-trials/data-sharing-clinical-trials</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03714672/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03714672/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant was enrolled on 26 August 2017.</recruitment_details>
      <pre_assignment_details>A total of 1151 participants signed an informed consent form, 829 participants were allocated to treatment. Of the 829 allocated participants, 3 were not treated (1 each in the Diclofenac 50, Tramadol 50, and Tramadol/Diclofenac 25/25 treatment arms) and were not included in the Safety Set (N=826).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tramadol/Diclofenac 50/50</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="P2">
          <title>Tramadol/Diclofenac 25/25</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="P3">
          <title>Tramadol 50</title>
          <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="P4">
          <title>Diclofenac 50</title>
          <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="206"/>
                <participants group_id="P4" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set (One participant was allocated to Tramadol/Diclofenac 50/50, but received Tramadol 50. The participant was included in the Tramadol 50 arm for the Safety Set as the analyses were conducted according to the treatment received)</population>
      <group_list>
        <group group_id="B1">
          <title>Tramadol/Diclofenac 50/50</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="B2">
          <title>Tramadol/Diclofenac 25/25</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="B3">
          <title>Tramadol 50</title>
          <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were be taken 8 hours apart.</description>
        </group>
        <group group_id="B4">
          <title>Diclofenac 50</title>
          <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were be taken 8 hours apart.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="208"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="206"/>
            <count group_id="B4" value="207"/>
            <count group_id="B5" value="826"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="207"/>
                    <measurement group_id="B5" value="826"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.9" lower_limit="18" upper_limit="41"/>
                    <measurement group_id="B2" value="24.0" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B3" value="23.8" lower_limit="18" upper_limit="41"/>
                    <measurement group_id="B4" value="23.6" lower_limit="18" upper_limit="56"/>
                    <measurement group_id="B5" value="23.6" lower_limit="18" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="529"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="206"/>
                    <measurement group_id="B5" value="824"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="803"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="207"/>
                    <measurement group_id="B5" value="826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" spread="4.08"/>
                    <measurement group_id="B2" value="25.0" spread="4.39"/>
                    <measurement group_id="B3" value="25.1" spread="4.25"/>
                    <measurement group_id="B4" value="24.5" spread="4.51"/>
                    <measurement group_id="B5" value="24.8" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline pain intensity categorized</title>
          <description>Measured using an 11-point NRS by answering the following question: &quot;Please rate your pain by selecting the one number that best describes how much pain you have right now.&quot; Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine, and were categorized as None (0), Mild (≥ 1 and &lt; 5), Moderate (≥ 5 and ≤ 6), and Severe (≥ 7). Baseline was the score assessed before the first dose of IMP.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="126"/>
                    <measurement group_id="B5" value="483"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline pain intensity 11-point NRS</title>
          <description>Measured using an 11-point NRS by answering the following question: “Please rate your pain by selecting the one number that best describes how much pain you have right now.” Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine, and were categorized as None (0), Mild (≥ 1 and &lt; 5), Moderate (≥ 5 and ≤ 6), and Severe (≥ 7). Baseline was the score assessed before the first dose of IMP.</description>
          <population>One participant (Tramadol/Diclofenac 25/25) from the Safety Set had no efficacy assessments and was not included in the Full Analysis Set.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="204"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="825"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="1.51"/>
                    <measurement group_id="B2" value="7.0" spread="1.45"/>
                    <measurement group_id="B3" value="7.0" spread="1.45"/>
                    <measurement group_id="B4" value="7.0" spread="1.40"/>
                    <measurement group_id="B5" value="7.0" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of molars extracted</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of molars extracted 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of molars extracted 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="164"/>
                    <measurement group_id="B5" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of surgery, minutes</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="21.90"/>
                    <measurement group_id="B2" value="35.0" spread="21.56"/>
                    <measurement group_id="B3" value="34.2" spread="20.25"/>
                    <measurement group_id="B4" value="32.9" spread="19.21"/>
                    <measurement group_id="B5" value="33.8" spread="20.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lidocaine used during surgery, mg</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211.1" spread="44.18"/>
                    <measurement group_id="B2" value="211.4" spread="41.13"/>
                    <measurement group_id="B3" value="211.3" spread="43.36"/>
                    <measurement group_id="B4" value="207.7" spread="42.13"/>
                    <measurement group_id="B5" value="210.4" spread="42.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>End of surgery to first dose of IMP, hours</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="206"/>
                    <count group_id="B4" value="207"/>
                    <count group_id="B5" value="826"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="0.89"/>
                    <measurement group_id="B2" value="2.2" spread="0.83"/>
                    <measurement group_id="B3" value="2.1" spread="0.90"/>
                    <measurement group_id="B4" value="2.1" spread="0.85"/>
                    <measurement group_id="B5" value="2.2" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)</title>
        <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point verbal rating scale (VRS) with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR4) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 4 hours after IMP intake. Minimum and maximum values for TOTPAR4 were 0=worst score and 16=best score, a higher score indicates more pain relief.</description>
        <time_frame>Up to 4 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)</title>
          <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point verbal rating scale (VRS) with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR4) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 4 hours after IMP intake. Minimum and maximum values for TOTPAR4 were 0=worst score and 16=best score, a higher score indicates more pain relief.</description>
          <population>Full Analysis Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="9.3" upper_limit="10.4"/>
                    <measurement group_id="O2" value="8.6" lower_limit="8.0" upper_limit="9.1"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.9" upper_limit="5.9"/>
                    <measurement group_id="O4" value="5.8" lower_limit="5.3" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bonferroni-Holm procedure used for determining the statistical significance of the results.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline pain intensity, and site as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
            <estimate_desc>LS means, 95% CIs, and pairwise CIs and p-values comparing the combination treatment arm to the monotherapy arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bonferroni-Holm procedure used for determining the statistical significance of the results.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline pain intensity, and site as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>-3.8</ci_upper_limit>
            <estimate_desc>LS means, 95% CIs, and pairwise CIs and p-values comparing the combination treatment arm to the monotherapy arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bonferroni-Holm procedure used for determining the statistical significance of the results. The planned test was a test for non-inferiority.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline pain intensity, and site as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
            <estimate_desc>LS means, 95% CIs, and pairwise CIs and p-values comparing the combination treatment arm to the monotherapy arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bonferroni-Holm procedure used for determining the statistical significance of the results. The planned test was a test for non-inferiority.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, baseline pain intensity, and site as covariates.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
            <estimate_desc>LS means, 95% CIs, and pairwise CIs and p-values comparing the combination treatment arm to the monotherapy arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief at 6 Hours Post-dose (TOTPAR6)</title>
        <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR6) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 6 hours after IMP intake. Minimum and maximum values for TOTPAR6 were 0=worst score and 24=best score, a higher score indicates more pain relief.</description>
        <time_frame>Up to 6 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief at 6 Hours Post-dose (TOTPAR6)</title>
          <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR6) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 6 hours after IMP intake. Minimum and maximum values for TOTPAR6 were 0=worst score and 24=best score, a higher score indicates more pain relief.</description>
          <population>Full Analysis Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="14.4" upper_limit="16.0"/>
                    <measurement group_id="O2" value="13.3" lower_limit="12.5" upper_limit="14.2"/>
                    <measurement group_id="O3" value="9.3" lower_limit="8.4" upper_limit="10.1"/>
                    <measurement group_id="O4" value="9.8" lower_limit="9.0" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief at 8 Hours Post-dose (TOTPAR8)</title>
        <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR8) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 8 hours after IMP intake. Minimum and maximum values for TOTPAR8 were 0=worst score and 32=best score, a higher score indicates more pain relief.</description>
        <time_frame>Up to 8 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief at 8 Hours Post-dose (TOTPAR8)</title>
          <description>Pain relief was assessed by the participant at defined time points after the first IMP dose using a 5-point VRS with categories 0 (none), 1 (a little), 2 (some), 3 (a lot), or 4 (complete). Total Pain Relief (TOTPAR8) is a time-weighted summary measure of the total area under the pain relief curve that integrates serial assessments of a participant's pain over the duration of 8 hours after IMP intake. Minimum and maximum values for TOTPAR8 were 0=worst score and 32=best score, a higher score indicates more pain relief.</description>
          <population>Full Analysis Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="19.0" upper_limit="21.2"/>
                    <measurement group_id="O2" value="17.8" lower_limit="16.7" upper_limit="18.9"/>
                    <measurement group_id="O3" value="13.1" lower_limit="12.0" upper_limit="14.2"/>
                    <measurement group_id="O4" value="13.7" lower_limit="12.6" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summed Pain Intensity Difference (SPID) at 4, 6, 8, and 24 Hours Post-dose</title>
        <description>Pain intensity was assessed by the participant before and at defined time points after the first IMP dose using an 11-point NRS with anchors at 0 for &quot;no pain&quot; and 10 for &quot;pain as bad as you can imagine&quot;. Pain Intensity Difference (PIDt) was defined as the difference between baseline pain intensity and pain intensity at time point t, and SPID defined as summed PIDt x [time (hours) elapsed since previous observation]. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum=10 at each time point], and negative numbers indicate an increase in pain [minimum=-10 at each time point]. The overall minimum and maximum are -10 and 10 times the number of hours specified (SPID-4=[-40 to 40], SPID-6=[-60 to 60], SPID-8=[-80 to 80], and SPID-24=[-240 to 240]).</description>
        <time_frame>Baseline; up to 24 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity Difference (SPID) at 4, 6, 8, and 24 Hours Post-dose</title>
          <description>Pain intensity was assessed by the participant before and at defined time points after the first IMP dose using an 11-point NRS with anchors at 0 for &quot;no pain&quot; and 10 for &quot;pain as bad as you can imagine&quot;. Pain Intensity Difference (PIDt) was defined as the difference between baseline pain intensity and pain intensity at time point t, and SPID defined as summed PIDt x [time (hours) elapsed since previous observation]. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum=10 at each time point], and negative numbers indicate an increase in pain [minimum=-10 at each time point]. The overall minimum and maximum are -10 and 10 times the number of hours specified (SPID-4=[-40 to 40], SPID-6=[-60 to 60], SPID-8=[-80 to 80], and SPID-24=[-240 to 240]).</description>
          <population>Full Analysis Set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.24" spread="0.564"/>
                    <measurement group_id="O2" value="13.67" spread="0.576"/>
                    <measurement group_id="O3" value="6.43" spread="0.570"/>
                    <measurement group_id="O4" value="7.72" spread="0.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.54" spread="0.836"/>
                    <measurement group_id="O2" value="21.86" spread="0.855"/>
                    <measurement group_id="O3" value="12.89" spread="0.845"/>
                    <measurement group_id="O4" value="14.36" spread="0.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.70" spread="1.121"/>
                    <measurement group_id="O2" value="28.90" spread="1.146"/>
                    <measurement group_id="O3" value="19.10" spread="1.133"/>
                    <measurement group_id="O4" value="20.54" spread="1.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.15" spread="3.787"/>
                    <measurement group_id="O2" value="91.99" spread="3.873"/>
                    <measurement group_id="O3" value="71.41" spread="3.828"/>
                    <measurement group_id="O4" value="72.08" spread="3.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve a 50 Percent Reduction in Baseline Pain (Pain at Least Half Gone)</title>
        <description>Time (hours) when the participant achieved a 50 percent reduction of baseline (starting) pain. It was assessed at defined time points after the first IMP dose using a YES or NO question for pain half gone.</description>
        <time_frame>Up to 24 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve a 50 Percent Reduction in Baseline Pain (Pain at Least Half Gone)</title>
          <description>Time (hours) when the participant achieved a 50 percent reduction of baseline (starting) pain. It was assessed at defined time points after the first IMP dose using a YES or NO question for pain half gone.</description>
          <population>Full Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.216"/>
                    <measurement group_id="O2" value="1.73" spread="2.778"/>
                    <measurement group_id="O3" value="3.01" spread="3.731"/>
                    <measurement group_id="O4" value="2.53" spread="2.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of First Perceptible Pain Relief</title>
        <description>Participants used one stopwatch to document the time between first IMP dose and when they begin to feel any pain-relieving effect from the IMP.</description>
        <time_frame>Up to 8 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of First Perceptible Pain Relief</title>
          <description>Participants used one stopwatch to document the time between first IMP dose and when they begin to feel any pain-relieving effect from the IMP.</description>
          <population>Full Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.483"/>
                    <measurement group_id="O2" value="0.67" spread="0.875"/>
                    <measurement group_id="O3" value="1.07" spread="1.000"/>
                    <measurement group_id="O4" value="1.12" spread="1.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Meaningful Pain Relief</title>
        <description>Participants used a second stopwatch to document the time between first IMP dose and when they felt their pain relief was meaningful to them.</description>
        <time_frame>Up to 8 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Meaningful Pain Relief</title>
          <description>Participants used a second stopwatch to document the time between first IMP dose and when they felt their pain relief was meaningful to them.</description>
          <population>Full Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="1.149"/>
                    <measurement group_id="O2" value="2.04" spread="1.810"/>
                    <measurement group_id="O3" value="2.93" spread="1.895"/>
                    <measurement group_id="O4" value="2.75" spread="1.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Intake of First Rescue Medication Dose</title>
        <description>The time from first IMP dose to first dose of rescue medication (ibuprofen or ketorolac), if needed, within 24 hours post-dose was calculated.</description>
        <time_frame>First dose to 24 hours after first dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Intake of First Rescue Medication Dose</title>
          <description>The time from first IMP dose to first dose of rescue medication (ibuprofen or ketorolac), if needed, within 24 hours post-dose was calculated.</description>
          <population>Full Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.84" spread="6.222"/>
                    <measurement group_id="O2" value="20.99" spread="7.450"/>
                    <measurement group_id="O3" value="17.37" spread="9.745"/>
                    <measurement group_id="O4" value="17.38" spread="9.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Global Evaluation of the Treatment</title>
        <description>Participants documented their overall impression of the analgesic efficacy of the IMPs on a 5-point Likert scale from Excellent (4) to Poor (0).</description>
        <time_frame>8 hours after the first dose of IMP or before first intake of rescue medication (whatever the first) and 24 hours after the first dose of IMPs</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Global Evaluation of the Treatment</title>
          <description>Participants documented their overall impression of the analgesic efficacy of the IMPs on a 5-point Likert scale from Excellent (4) to Poor (0).</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8-Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="197"/>
                    <count group_id="O4" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="205"/>
                    <count group_id="O4" value="206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Type of Adverse Events</title>
        <description>The incidence of treatment emergent adverse events (TEAE) reported from first dose (Day 1) to last scheduled contact with the participant on Day 14 was descriptively summarized. Selected TEAEs were events with preferred terms of nausea, vomiting, abdominal pain, gastrointestinal bleeding, dizziness, or hypotension.</description>
        <time_frame>Day 1 to Day 14</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol/Diclofenac 50/50</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O2">
            <title>Tramadol/Diclofenac 25/25</title>
            <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 50</title>
            <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
          <group group_id="O4">
            <title>Diclofenac 50</title>
            <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Type of Adverse Events</title>
          <description>The incidence of treatment emergent adverse events (TEAE) reported from first dose (Day 1) to last scheduled contact with the participant on Day 14 was descriptively summarized. Selected TEAEs were events with preferred terms of nausea, vomiting, abdominal pain, gastrointestinal bleeding, dizziness, or hypotension.</description>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to IMP or rescue medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE with outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selected TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to IMP withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose reduction, interruption, or withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Day 14</time_frame>
      <desc>Sites were instructed not to report dental pain as an AE until 24 hours after the first dose of IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tramadol/Diclofenac 50/50</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 50/50: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="E2">
          <title>Tramadol/Diclofenac 25/25</title>
          <description>Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol/Diclofenac 25/25: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="E3">
          <title>Tramadol 50</title>
          <description>Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Tramadol 50: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
        <group group_id="E4">
          <title>Diclofenac 50</title>
          <description>Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
Diclofenac 50: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="206"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="51" subjects_at_risk="208"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E3" events="62" subjects_affected="52" subjects_at_risk="206"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="57" subjects_affected="41" subjects_at_risk="208"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E3" events="75" subjects_affected="44" subjects_at_risk="206"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="208"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="206"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="208"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" events="34" subjects_affected="29" subjects_at_risk="206"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="208"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="206"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Helpdesk</name_or_title>
      <organization>Grünenthal GmbH</organization>
      <phone>+49 241 569 ext 3223</phone>
      <email>clinical-trials@grunenthal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

